直接PCI的STEMI患者内源性纤溶受损可预测复发性心血管事件:RISK PPCI研究
该前瞻性观察研究纳入496例接受直接PCI的STEMI患者,用即时全血栓检测法在入院、出院和30天评估血栓状态,随访1年主要不良心血管事件。14%患者存在内源性纤溶受损(基线溶解时间≥2500秒),可高度预测复发性MACE(HR 9.1),主要由心血管死亡和心肌梗死驱动。
要点
- 接受直接PCI和DAPT的STEMI患者中,14%存在内源性纤溶受损。
- 纤溶受损预测1年复发性MACE,校正传统危险因素后HR为8.03。
- 加入纤溶受损指标使复发性MACE预测改善超过50%。
核心结论
- 内源性纤溶评估可识别直接PCI和DAPT后仍处于极高心血管风险的STEMI患者。
研究设计与样本
- 前瞻性观察研究纳入496例接受直接PCI的STEMI患者,入院、出院和30天用即时全血栓检测法评估血栓状态,随访1年。
主要发现
- 14%患者基线纤溶时间≥2500秒,定义为内源性纤溶显著受损。
- 纤溶受损预测复发性MACE(HR 9.1,95%CI 5.29-15.75,P<0.001),主要由心血管死亡(HR 18.5,95%CI 7.69-44.31,P<0.001)和心肌梗死(HR 6.2,95%CI 2.64-14.73,P<0.001)驱动,尤其30天内。
- 校正传统危险因素后纤溶受损仍强预测MACE(HR 8.03,95%CI 4.28-15.03,P<0.001)。
- 加入纤溶受损使复发性MACE预测改善超过50%(P<0.001)。
- PCI前自发ST段回落者纤溶更快更有效[LT 1050(1004-1125)秒 vs. 1501(1239-1997)秒,P<0.001]。
关键数值与推荐
- 基线纤溶时间≥2500秒定义为内源性纤溶显著受损。
- 纤溶时间不受包括DAPT在内的标准STEMI治疗影响,30天时无变化。
临床怎么用
- 可考虑用即时全血栓检测法评估STEMI患者内源性纤溶状态以识别高危者。
- 纤溶受损患者可能需要额外个体化抗栓/抗凝治疗,但尚需进一步研究验证。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The endogenous fibrinolytic system serves to prevent lasting thrombotic occlusion and infarction following initiation of coronary thrombosis. We aimed to determine whether impaired endogenous fibrinolysis can identify patients with ST-segment elevation myocardial infarction (STEMI) who remain at high cardiovascular risk despite dual antiplatelet therapy (DAPT). METHODS AND RESULTS: A prospective, observational study was conducted in 496 patients presenting with STEMI for primary percutaneous coronary intervention (PPCI). Blood was tested on arrival pre-PPCI, at discharge and at 30 days to assess thrombotic status using the automated point-of-care global thrombosis test and patients followed for 1 year for major adverse cardiovascular events (MACEs). Endogenous fibrinolysis was significantly impaired [baseline lysis time (LT) ≥2500 s] in 14% of patients and was highly predictive of recurrent MACE [hazard ratio (HR) 9.1, 95% confidence interval (CI) 5.29-15.75; P < 0.001], driven by cardiovascular death (HR 18.5, 95% CI 7.69-44.31; P < 0.001) and myocardial infarction (HR 6.2, 95% CI 2.64-14.73; P < 0.001), particularly within 30 days. Fibrinolysis remained strongly predictive of MACE after adjustment for conventional risk factors (HR 8.03, 95% CI 4.28-15.03; P < 0.001). Net reclassification showed that adding impaired fibrinolysis improved the prediction of recurrent MACE by >50% (P < 0.001). Patients with spontaneous ST-segment resolution pre-PPCI had more rapid, effective fibrinolysis [LT 1050 (1004-1125) s vs. 1501 (1239-1997) s, P < 0.001] than those without. Lysis time was not altered by standard of care STEMI treatment including DAPT and was unchanged at 30 days. CONCLUSION: Endogenous fibrinolysis assessment can identify patients with STEMI who remain at very high cardiovascular risk despite PPCI and DAPT. Further studies are needed to assess whether these patients may benefit from additional, personalized antithrombotic/anticoagulant medication to reduce future cardiovascular risk. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT02562690.
引用
- Farag M, Spinthakis N, Gue YX, et al. Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. Eur Heart J. 2019. PMID: 30380032. doi:10.1093/eurheartj/ehy656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。